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Abstract. The question of a mathematical representation and theoretical overcoming by op-
timised therapeutic strategies of drug-induced drug resistance in cancer cell populations is
tackled here from the point of view of adaptive dynamics and optimal population growth
control, using integro-differential equations. Combined impacts of external continuous-time
functions, standing for drug actions, on targets in a plastic (i.e., able to quickly change its
phenotype in deadly environmental conditions) cell population model, represent a thera-
peutical control to be optimised. A justification for the introduction of the adaptive dynam-
ics setting, retaining such plasticity for cancer cell populations, is firstly presented in light of
the evolution of multicellular species and disruptions in multicellularity coherence that are
characteristics of cancer and of its progression. Finally, open general questions on cancer and
evolution in the Darwinian sense are listed, that may open innovative tracks in modelling
and treating cancer by circumventing drug resistance. This study sums up results that were
presented at the international NUMACH workshop, Mulhouse, France, in July 2018.
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1 Introduction
This study presents an evolutionary viewpoint on cancer, seen as the 2 time scales of (large-
time) evolution in the genomes and of (short-time) evolution in the epigenetic landscape of
a constituted genome, which led to the proposal of mathematical models elaborated within
the Jacques-Louis Lions laboratory of Sorbonne Université, Paris. These views, inspired by
works of Lineweaver, Davies and Vincent (cancer as anatomically located backward evolution
in multicellular organisms, aka atavistic theory of cancer) and of Sui Huang and collaborators
(revisited Waddington epigenetic landscape), respectively, may serve as guidelines to propose
a global conception of cancer, including towards possible innovating therapeutic strategies.
Drug-induced drug resistance in cancer, the biological and medical question we are tack-
ling from a theoretical point of view, may be due to biological mechanisms of different natures,
mere local regulation, epigenetic modifications (reversible, nevertheless heritable) or genetic
mutations (irreversible), according to the extent to which the genome of the cells in the popula-
tion is affected. In this respect, the modelling framework of adaptive dynamics presented here
is likely to biologically correspond to epigenetic modifications, although eventual induction
of emergent resistant cell clones due to mutations under drug pressure is not to be excluded.
From the biologist’s point of view, we study phenotypically heterogeneous, but genetically
homogeneous, cancer cell populations under stress by drugs.
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The built-in targets for theoretical therapeutic control present in the phenotype-structured
PDE models we advocate are not supposed to represent well-defined molecular effects of the
drugs in use, but rather functional effects, i.e., related to cell death (cytotoxic drugs), or to pro-
liferation in the sense of slowing down the cell division cycle without killing cells (cytostatic
drugs). I propose that cell life-threatening drugs (cytotoxics) induce by far more resistance in
the highly plastic cancer cell populations than drugs that only limit their growth (cytostatics),
and that a rational combination of the two classes of drugs - and possibly others, adding rele-
vant targets to the model - may be optimised to propose therapeutic control strategies to avoid
the emergence of drug resistance in tumours.
We address this optimal control problem in the context of two populations, healthy and
cancer, both endowed with phenotypes evolving under drug pressure acting as an environ-
mental constraint, and reciprocally inhibiting the proliferation of the other population in a
non-local Lotka-Volterra model. Our objective is thus to minimise the proliferation of a cancer
cell population while limiting the emergence of drug resistance in it, and taking into account
the constraint of limiting toxicity to a population of healthy cells, that are also targets of un-
wanted adverse effects of the cytotoxic drug.
To conclude, I present an informal list of open questions on cancer and its treatments that
may be considered as challenges to mathematicians (and others).
2 Biological background on evolution and cancer
2.1 Motivation from, and focus on, drug resistance in cancer
Intra-tumour heterogeneity with respect to drug resistance potential, modelling between-cell
phenotypic variability within cancer cell populations, is a convenient setting to represent con-
tinuous evolution towards drug resistance in tumours [6]. Going beyond the small scale of
a human life, I will consider slow genetic mechanisms of ‘the great evolution’ that has de-
signed multicellular organisms (see Figure 1), in the frame of which fast reverse evolution on
smaller time windows, at the scale of a human disease, may explain transient or established
drug resistance. The idea of cancer as a backwards evolution towards unicellularity, although
not new [2, 23], has recently be popularised as the atavistic theory of cancer, with many recent
developments [4, 8, 10, 43, 44, 48].
A key concept to be added to reverse evolution, i.e., to the atavistic hypothesis, is the high
plasticity shown by cancer cells, due to epigenetic (much faster than genetic mutations, and
reversible) propension to reversal to a stem-like, de-differentiated (hence plastic) status, result-
ing in fast adaptability of cancer cell populations, makes them amenable to resist abrupt drug
insult as response to extreme cellular stress [15, 16].
Such plasticity, itself reversible according to environmental pressure or relaxation, is cap-
tured by mathematical models that incorporate between-cell heterogeneity by making use of
continuous phenotypic variables structuring the population [29, 30]. Such models have the
advantage of being compatible with optimal control methods for the theoretical design of op-
timised therapeutic protocols involving combinations of cytotoxic and cytostatic (and later epi-
genetic?) treatments [39].
2.2 Drug resistance: a phenomenon common to various therapeutic situations
In therapeutic situations where an external pathogenic agent is proliferating at the expense
of the resources of an organism: antibiotherapy, virology, parasitology, target populations are
able to develop drug resistance mechanisms (e.g., expression of β-lactamase in bacteria ex-
posed to amoxicillin). In cancer, there is no external pathogenic agent (even though one may
have favoured the disease) and the target cell populations share much of their genome with
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Figure 1: Schematic timeline of the evolution of life on Earth, emphasising emergence of multicellularity between -1000
and -500 million years from now (taken from [6]).
the host healthy cell population, making overexpression of natural defence phenomena easy
(e.g., ABC transporters in cancer cells).
Drug resistance may account for unexpected failures in targeted therapies, as they are
meant to block a given intracellular (or intercellular) signalling pathway, very often related
to proliferation, that can be coped with by adaptable, plastic cancer cells [14]. Note that drug
resistance (and resistance to radiotherapy) is one of the many forms of fast resistance to cellu-
lar stress, possibly coded in ‘cold’, i.e., strongly preserved throughout evolution, rather than
in ‘hot’, i.e., mutation-prone, genes [50].
Overexpression of ABC transporters [18], of drug processing enzymes, decrease of drug
cellular influx, etc. [17] are relevant to describe molecular resistance mechanisms at the single
cell level. However, at the cell population level, representing drug resistance by a continuously
evolving abstract variable x standing for the expression of a phenotype of resistance to a given
cytotoxic drug is adapted to describe in a one-dimensional way evolution from total sensitivity
(x=0) towards total resistance (x=1), and such abstract variable could be partly identified by
measuring the expression of ABC transporters such as P-glycoprotein (aka MDR1) [37].
Is such evolution towards drug resistance due to sheer Darwinian selection of the fittest by
mutations in differentiation at cell division or, at least partially, due to phenotype adaptation
in individual cells at the epigenetic level of the chromatin? A unique answer to this question
does not result clearly from biological experiments, and indeed observations exist, showing
that non-Darwinian phenomena, sometimes elicited to be of epigenetic nature, may explain
such reversible evolution towards drug resistance in cancer cell populations [41].
2.3 A possible evolutionary framework (long-term view): the atavistic hypothesis of
cancer
“Nothing in biology makes sense except in the light of evolution” [11]
“Cancer: more archeoplasm than neoplasm” [48]
The atavistic hypothesis of cancer [4, 8,10,43,44,48] states that cancer is a coarse, primitive
state of multicellularity development that nevertheless involves all our genome. In this way,
cancer represents a step in the reversion of the evolution of multicellular organisms towards
(but not until) unicellular life.
A reasonable hypothesis, coming from the observation that cancer is a disease of the control
and coherence of multicellularity, is that the genes that have appeared in the process of devel-
opment to multicellularity are precisely those that are altered in cancer [10]. In the framework
of cancer evolution in a single organism, in what order do these genes come altered? Ad-
mitting that the building of multicellularity starts in assemblies of cells by developing gene
expression from 1) proliferation+apoptosis to 2) cell differentiation +division of work, and
to 3) epigenetic control of differentiation and proliferation, this question is partially answered
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in [19] about acute myeloid leukaemia (AML) by phylogenetic studies on fresh blood samples
from patients: it is likely to be, in the standard scenario in which p53 is not mutated (case of
most AMLs), the reverse order, i.e., firstly mutation of an epigenetic control gene, then of a
transcription factor corresponding to differentiation, and, only finally in this phylogeny, of a
gene controlling proliferation.
Identifying those genes is of high interest, as reconstituting the phylogeny of this ‘mul-
ticellularity toolkit’ [12, 13, 52] should shed light on the robustness or fragility of genes (in a
given organism) that have been altered in cancer. According to the atavistic hypothesis [10],
cancer is a ‘backward evolution’ from a sophisticated form of multicellularity (us), in which
epigenetic processes control gene regulatory networks of transcription factors: differentiation
factors, p53, etc., that themselves physiologically control the basis of cellular life: proliferation.
Following this point of view, i.e., that building multicellularity from coarse (proliferation) to
fine (epigenetic control of differentiation) mechanisms, it is clear indeed that attacking cancer
on proliferation is precisely attacking its most robust basis. It would be better to attack its
weaknesses (e.g., absence of adaptive immune response) [26].
Furthermore, we bear in our genomes many attempts of species evolution since billions
of years; dead-end tracks (‘unused attractors’ in S. Huang’s and S. Kauffman’s version of the
Waddington landscape, cf. infra [21, 22]) have been normally barred by Darwinian selection
(e.g., silenced by epigenetic enzymes, resulting in evolutionary barriers in this landscape), but
are still there, waiting to be triggered by the pressure of a changing environment. In can-
cer, global regulations (such as coherence messages from a central circadian clock) are lost,
differentiation is out of control, so that, without regulation, local proliferations overcome; so-
phisticated adaptive epigenetic mechanisms are present, not controlling proliferation, but serving
it (possibly recruited in the context of extreme cellular stress by stochastic or systematic ex-
pression of so-called cold genes? [50]).
Primitive forms of cooperation between specialised cells in a locally organised multicellu-
lar collection (tumour), with much plasticity among them, may be present, exhibiting coherent
intratumoral heterogeneity, and escaping external control [31, 36, 42]. Tumours are thus Meta-
zoa 1.0 [10]. The basic cancer cell, be it isolated or included in a tumour is thus highly plastic
(undifferentiated or able to easily dedifferentiate) and highly capable of adaptation to a hostile
environment, as were its ancestors in a remote past of our planet (poor O2, acidic environment,
high UV radiations,...) [10] and likely presently even more.
2.4 Another evolutionary framework (life-term view): revisiting the Waddington
epigenetic landscape
“Nothing in evolution makes sense except in the light of systems biology” (S. Huang, 2012)
At the time scale of the development of a human life, for a given subject, the relevant time
evolution is the one of a coherent succession of differentiations from one primitive cell towards a
completely mature multicellular organism. This differentiation process, consisting of epigenetic
modifications (aka epimutations) within the same genome, is metaphorically represented by the
classic Waddington epigenetic landscape [49], illustrated on Figure 2, later revisited by Sui
Huang [21, 22], illustrated on Figure 3.
When the coherence in the multicellular design of an individual is altered by blockade
of cell differentiation at a given stage and in a given organ, with maintained proliferation,
in one of what S. Huang calls unused attractors in the Waddington epigenetic landscape, see
Figure 3, then can locally begin cancer. Such defect in local differentiation control may be due
to mutations of epigenetic control genes (e.g., in the case of acute myeloid leukaemia (AML),
TET2, DNMT3A, leading in a process that may take years, from absolute clinical and biological
silence in early infancy, to the clinical manifestation of an AML, in an elderly patient). It can
also be due to the local action of external carcinogenic agents, including anticancer drugs that
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Figure 2: The classic Waddington landscape (1957) for cell differentiation [49]
Figure 3: The Waddington landscape revisited by Sui Huang (2011, 2013) [21, 22]
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destabilise the genome, or to random mutations (less likely, and these can also result from
prior epimutations [51]).
From the point of view of this metaphoric landscape, the plasticity of cancer cell popula-
tions can be seen as plasticity of the landscape (somehow from a rigid plaster-like to a smooth
plasticine-like construction, erasing epigenetic barriers between valleys and (since the third
dimension in the scenery represents differentiation potential of an initial totipotent cell) thor-
oughly flattening the whole landscape, resulting in a more and more poorly differentiated and
incoherent multicellular ensemble of cells.
3 Cell population adaptive dynamics
3.1 First model with (epi)mutation kernel, healthy and cancer cell population [29]
Triggered by the fact that drug-induced drug resistance remains one of the main pitfalls and
causes of death in the clinic of cancers, with the aim to later optimise drug delivery strategies
to circumvent it, we proposed a drug resistance phenotype-structured model in which the
phenotype x∈ [0,1] (from 0, total sensitivity, to 1, total resistance) was present in 4 terms: the
basic proliferation rate r, the basic (without drugs added) death rate d, a drug sensitivity term
µC, and an integral term representing small mutations or epimutations, i.e., small changes in
phenotype.
This first integro-differential model structured in a continuous trait x representing the level
of expression of a drug resistance phenotype (to a given drug), with variables representing the
evolution of two cell populations, healthy and cancer, nH(x,t), nC(x,t) being the densities of















where r(x)= basic reproduction rate, d(x)= basic death rate; we assume that
r(0)>d(0)>0, r′(·)<0, r(1)=0, d′(·)>0
Here θH, θC (1> θC >> θH ≥ 0) are the proportions of divisions with mutations; µ[H,C](x)
(with µ′C(·)<0) represents the phenotype-dependent response to cytotoxic drug, with concen-
tration u(t), designed to target cancer cells.
The assumptions r(·)> 0,µC(·)> 0, µ′C(·)< 0 and r′(·)< 0 (cost of resistance: the higher is x,
the lower is proliferation) represent the effect of drug resistance on the proliferation and death
terms, plus an evolutionary double bind on resistant cancer cell populations, i.e., a trade-off between
growing (thus getting exposed) and keeping still (thus surviving).
Here u(t) denotes the instantaneous dose (concentration) of chemotherapy, only environ-
mental pressure considered in this model. We assume that its effect is cytotoxic, i.e., on the
death term only.
We then have the
Theorem 3.1. [29] (Resistant cell population case) There is monomorphic evolution of the cell popula-
tion towards drug-induced drug resistance (illustrated on Figure 4).
In the same way, we represent the sensitive (or healthy) population case (same notations):
(Sensitive cancer - or healthy - case)
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Figure 4: Resistant cancer cell population case. Left panel: starting from an arbitrary median phenotype x=0.5, level
sets of a drug-resistant population in the (t,x) (time and phenotype) plane. Right panel: asymptotic distribution of
this drug-resistant population according to the drug resistance phenotype x∈ [0,1]. [Resistant cancer cell population
case: illustration of Gause’s exclusion principle] here with θC =0, µC(·)>0, r′(·)<0, µ′C(·)<0 (costly drug-induced























x=0 nC(x,t)dx. (β>0 imposes healthy tissue homeostasis.)
We then have the
Theorem 3.2. [29] (Sensitive cell population case) There is monomorphic evolution of the cell popula-
tion towards drug sensitivity (illustrated on Figure 5).
However, whatever the qualities of this model, and its amenability to be analysed mathe-
matically, we found out that the integral term resulted in a negligible part to the evolution of
the trait in the population, and that almost all was due to the sensitivity term µC in the resistant
cancer case. We thus reverted to another form of model, still nonlocal, but of the more clas-
sical Lotka-Volterra form, in which nonlocality is located in the logistic term, that represents
limitation of growth by competition of every cell with all the others in the population, e.g.,
for space and nutriments. Note that an important characteristic of these integro-differential
models, from a biological point of view, is that their evolution is totally reversible, i.e., if the
environmental pressure represented by the drug infusion is withdrawn, then the model reverts
to its drug-free status, and this is observed indeed in phenomena of acute drug resistance in
cancer cell populations [41].
3.2 Simple phenotype-structured population dynamics
In the most general case, we aim at the description of the evolution of a population in time t and
in relevant phenotype x, where the ‘structure variable’ x is a trait chosen as bearing the biological
variability at stake, e.g. here (but many other instances may exist, such as cell size, age in cell
division cycle, fecundity, viability, motility, etc., depending on the context), a resistance trait.
The variable at stake, n(t,x), represents a population density of individuals bearing trait x
at time t. We investigate
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Figure 5: Healthy (or sensitive) cell population case. Left panel: starting from an arbitrary median phenotype x= 0.5,
level sets of a drug-sensitive population in the (t,x) plane (time in abscissae and phenotype in ordinates). Right panel:
asymptotic distribution of this population according to the drug resistance phenotype x∈ [0,1]. [Sensitive (or healthy)
cell population case: again, illustration of Gause’s exclusion principle] here with θH =0 (no mutations) and µH =0 (no
drug-induced resistance), with u(t)=Cst [29]




n(t,x)dx (if, e.g., x∈ [0,1])




In the case of cancer cell populations:
(1) allows to study tumour growth;
(2) allows to study the evolution and asymptotic distribution of the trait.
Note that space is not necessarily a relevant structure variable when studying drug control.
We then propose a nonlocal (it is the logistic term which is nonlocal) Lotka-Volterra model:













We assume reasonable (C1) hypotheses on r and d, and n0∈L1([0,1]).
We then tackle the two questions above: what is the asymptotic behaviour (t→+∞) of
(1) the total population ρ(t)?








, i.e., to the smallest value ρ such that
r(x)−d(x)ρ≤0 on [0,1]. Secondly, we have concentration in x on a zero-measure set.
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Figure 6: Convergence (one-population case): plot of t 7→ρ(t)
Figure 7: Concentration: plot of the distribution of phenotype x in the population n(t,x) for different times t
Theorem 3.3. (i) ρ converges to ρ∞, the smallest value ρ such that r(x)−d(x)ρ≤0 on [0,1].





(iii) Furthermore, if this set is reduced to a singleton x∞, then n(t,·)⇀ ρ∞δx∞ in M1(0,1), where
M1(0,1) is the space of bounded measures on [0,1], dual of the space of continuous functions C0([0,1],R).
Proof of the theorem (1-population case), obtaining simultaneously convergence and con-
centration by using a Lyapunov function:
Although in the 1D case a direct proof of convergence based on a bounded variation (BV)
hypothesis may be obtained, from which concentration easily follows due to the exponential
nature of the solutions, it is interesting to note, as this argument can be used in the case of 2
populations, see below Section3.4, that a global proof based on the design of a Lyapunov function








, and for an appropriate weight w(x) (in fact 1d(x) ) setting












which is always nonpositive, tends to zero for t→∞, thus making V a Lyapunov function, and
showing at the same time convergence and concentration. Indeed, in this expression, the two
terms are nonpositive and their sum tends to zero; the zero limit of the first one accounts for
convergence of ρ(t), and the zero limit of the second one accounts for concentration in x (on a
zero-measure set) of lim
t→+∞
n(t,x).
Note that this kind of nonlocal integrodifferential model can be enriched to become a
reaction-diffusion, or reaction-diffusion-advection model, studied numerically, e.g., in [27,28].
3.3 Non-local Lotka-Volterra 2D model (2 populations, healthy, H, and cancer, C)
with 2 different drugs and one resistance phenotype x
A natural extension of the previous nonlocal Lotka-Volterra model to 2 populations, one healthy



















where we define an ‘environment’ function standing for the nonlocal logistic term (without
added drug): IH(t) = aHH.ρH(t)+aHC.ρC(t), IC(t) = aCH.ρH(t)+aCC.ρC(t), with aCH << aCC
and aHC << aHH (intraspecific competition - within the same niche - being always higher than




0 nC(t,x)dx, u1 being a cytotoxic
drug, u2 a cytostatic drug. In this setting, the cytotoxic drug u1 acts as an added death term,
whereas the cytostatic drug u1 only slows down proliferation without killing cells, at least at
low doses (u1 can be thought of as a targeted therapy, e.g., a tyrosine kinase inhibitor).
As a proof of concept, so far without a theorem, an illustration of possible behaviours for
the 2 cell populations is shown on Figures 8 and 9. By increasing the drug doses, one can
obtain extinction of the cancer cell population while the healthy cell population is preserved.
3.4 Asymptotic behaviour with constant controls for the nonlocal 2-population
case Lotka-Volterra model: a theorem
Following an argument by P.-E. Jabin & G. Raoul [24], it can be proved that convergence and
concentration occur simultaneously by making use of a Lyapunov functional of the form∫
w(x){n(t,x)−n∞(x)−n∞(x)lnn(t,x)} dx
Theorem 3.4. [39]
(Asymptotic behaviour theorem, generalising to 2 populations the 1D case)
Assume that u1 and u2 are constant: u1≡ ū1, and u2≡ ū2. Then, for any positive initial population
of healthy and of tumour cells, (ρH(t),ρC(t)) converges to the equilibrium point (ρ∞H ,ρ
∞
C ), which can
be exactly computed as follows:
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Figure 8: Healthy (or sensitive) cell population case. Simultaneous combinations of 2 drugs, one cytotoxic (u1) and one
cytostatic (u2), with increasing equal constant doses. Proof of concept, or here “Pedestrian’s optimisation”, illustrated
in the (x,t) plane (resistance phenotype in abscissae and time in ordinates). Increasing constant and equal doses of
the 2 drugs, from 0 to 1, 1.5 and 2 (arbitrary units), to be read from left to right, first line of 2, then second line of
2: healthy cells are preserved. [29].
Figure 9: Resistant cancer cell population case. Simultaneous combinations of 2 drugs, one cytotoxic (u1) and one
cytostatic (u2), with increasing equal constant doses. Proof of concept, or here “Pedestrian’s optimisation”, illustrated
in the (x,t) plane (resistance phenotype in abscissae and time in ordinates). Increasing constant and equal doses of
the 2 drugs, from 0 to 1, 1.5 and 2 (arbitrary units), to be read from left to right, first line of 2, then second line of 2:
initially as sensitive as healthy cells, cancer cells develop resistance, however to an insufficient level, and eventually go
to extinction. A successful example of risky (as shown indeed in Section 4.1) massive drug delivery in a population of
cancer cells that are not amenable to develop enough resistance [29].
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Let AH⊂ [0,1] (resp., AC⊂ [0,1]) be the set of all points x∈ [0,1] such that equality hold in one of








converge respectively to AH and AC as t tends to +∞.
This theorem, proved by a Lyapunov functional argument (and of which, contrary to the
1D case, we do not know any proof otherwise) can furthermore be generalised to the case of
N>2 interacting populations [40] (even though those N populations do not represent cancer
and healthy cell populations any more), by making use of the same Lyapunov argument.
Note that in the initial framework of 2 populations, healthy and cancer, detailed numerical
studies have recently been led in a close, but more general setting by other authors [7].
4 Therapeutic control
4.1 How to be deleterious by using constant and high doses of drugs
It is a well-known fact in many therapeutic situations, in particular in antibiotherapy and in
oncology, that exposing an organism, whose proliferation must be fought, to constant and high
doses of drugs is the best way to end up with resistance to the treatment and total therapeu-
tic inefficacy. Figure 10 illustrates on an example a phenomenon indeed common to many
therapeutic situations, the fact that the use of massive drug doses in a constant schedule on
populations of living organisms with the aim to eradicate them constantly leads to resistance
to the drug.
This resistance-inducing killing effect (‘What does not kill me strengthens me’ [38], paraphras-
ing Nietzsche) should be avoided as long as possible in therapeutics. In summary (and this
will be shown in the next section): limit proliferation but do not try too hard to kill cells, lest the
cell population should become resistant, and rather give cytotoxics at high doses (maximum
tolerated dose, MTD) during a short interval of time only, thus avoiding to trigger resistance.
Note that the cytostatic drug u2 only slows down proliferation (softly slowing down velocity in
the cell division cycle), but does not arrest it, at least at low doses, whereas the cytotoxic drug
u1 kills the cells by increasing the death term, hence it is actually a direct life threat to the cell
population, that ‘defends itself’ (by biological mechanisms that are partly known, linked to its
plasticity, not represented here).
Also note that an alternative strategy to such use of MTD is metronomic therapy, that seems
to prevent the development of resistance by giving low doses of cytotoxics over an extended
period of time, likely expecting that the population, to some extent thwarted in its prolifera-
tion, will be kept in check by the immune system. This has not been represented in our optimal
control perspective thus far (however, see [5]).
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Figure 10: What should never be done (the deleterious therapy): Starting from a Gaussian-like distribution of the resistance
phenotype on the whole interval for the two populations, exposed to constant and high dose delivery of the cytotoxic
drug, one can observe strikingly different results for its asymptotic distribution: quite small effects of the drug pressure
on the phenotype of the healthy (sensitive) cell population nH , while the resistant one nC quickly concentrates around
a resistant phenotype. First 2 figures, left: distributions of the resistance phenotype x in the 2 populations, healthy
(1st) and cancer (2nd). Together with this phenotype concentration effect, one can observe on the other 4 figures the
catastrophic effects of this drug delivery strategy on 1) the total cell population of cancer cells ρC(t)=
∫ 1
0 nC(t,x)dx,
2) the ratio of healthy cells ρH over the total cell population ρH+ρC, 3) the population of sensitive cancer cells
ρCS(t) :=
∫ 1
0 (1−x)nC(t,x)dx, and 4) the total population of healthy cells ρH(t)=
∫ 1
0 nH(t,x)dx [39].
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4.2 Optimal control problem, 2-population nonlocal Lotka-Volterra model
The cell environment being defined as in Section 3.3 for each one of the two populations
nH and nC as a linear combination of the two total cell populations: IH(t) = aHH.ρH(t)+
aHC.ρC(t), IC(t)=aCH.ρH(t)+aCC.ρC(t), in which coefficients a·· represent the intensity of inter-
actions between them (competition being much stronger within a niche than between niches,





optimal control problem for the integro-differential model with evolution in the expression x

























under the additional constraints
ρH(t)
ρH(t)+ρC(t)
≥ θHC, ρH(t)≥ θH.ρH(0)
(the last constraint, with, e.g., θH =0.6, is here to limit damage to healthy cells)
Theorem 4.1. (Optimal control theorem) [39]
Under these conditions, the optimal trajectory in large time T>0 consists of 2 parts:
• a long-time part, with constant controls on [0,T1], at the end of which populations have almost
concentrated in phenotype (for T1 large)
• a short-time part on [T1,T] consisting of at most three arcs, for T−T1 small:




2. a free arc (no constraint saturating) with controls u1=umax1 and u2=u
max
2 ,
3. a boundary arc along the constraint ρH(t)≥ θH.ρH(0) with u2=umax2 .
The second short-time phase is all the more efficient as the phenotypes are more concen-
trated (hence, as the time T is large).
Figure 11 illustrates this theorem by simulations (optimisation using AMPL-IPOPT) for
T=30 and for T=60.
The main idea to interpret this theorem is the following:
1. Let the system naturally evolve to a phenotype concentration (long-time phase).
2. Then, apply the maximal quantity of drugs, during a short-time phase, in order to eradi-
cate as many tumour cells as possible.
Note that this strategy lets the cancer cell population ρC grow initially to an equilibrium
level, while increasing the ratio
ρCS
ρC
of drug-sensitive cancer cells, before delivering u1=umax1 ;
only then is the cytotoxic efficacy maximal.
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Figure 11: Solution to the optimal control problem for T=30 (upper eight panels) and for T=60 (lower eight panels).
Same sequence of 6 first figures as in Figure 10, plus optimal control solutions for cytotoxic u1 and cytostatic u2 (last 2
figures). Note that the optimal control strategy lets the cancer cell population ρC grow initially to an equilibrium level,
while increasing the ratio
ρCS
ρC
of drug-sensitive cancer cells, before delivering u1 = umax1 ; only then is the cytotoxic
treatment efficacy maximal. The optimal control trajectory for the cytotoxic drug is made of 3 parts, the first one
with u1 =0, the 2nd one with u1 =umax1 , the 3rd one with u1 slightly lower than u
max
1 [39]. The horizon T is fixed,
and the switching time T1 changes with T, but the behaviour of the solutions is the same, whatever the value of T.
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4.3 Mixed phenotype-spatial model (simulations without optimal control) [30]
In this section, we investigate (only by simulations) a model in which, contrary to the previous
ones, Cartesian space is represented. Whereas it does not necessarily make sense to set spatial
variables to represent a tumour setting where nothing is known of the tumour geometry - and
indeed, tumour geometries can be difficult to define, in particular for malignant haemopathies,
that are liquid tumours of the bone marrow - spatially structured solid tumours exist, and
they frequently adopt at their initial, non vascularised, stage the shape of spheroids. In such
tumours, the outer rim is the place where both nutrients (glucose,oxygen) and anticancer drugs
are received. Below is proposed such a spatial model, with representation of the effects of
different combinations of cytotoxic (u1) and cytostatic (u2) drugs, that nevertheless takes into
account the issue of drug-induced drug resistance.
Here, both a 1D (radial, for a tumour spheroid) spatial variable r and a resistance pheno-
type x are considered as structuring a population of cancer cells able to develop resistance. We
assume that the evolution of functions n cell population), s (nutrients), u1 and u2 (drug con-

































with zero Neumann conditions at r=0 coming from radial symmetry and Dirichlet boundary
conditions at r=1
s(t,r=1)= s1, ∂rs(t,r=0)=0, u1,2(t,r=1)=u1,2(t), ∂ru1,2(t,r=0)=0. (4.5)
In these equations, the first one describing proliferation of the cancer cell population, the
other three representing diffusion in space, from the rim r = 1 toward the center r = 0 of the
spheroid, of a nutrient s (standing for oxygen, glucose, fatty acids, etc., addressing prolifer-
ation) and of the two drugs u1 and u2 (addressing the added death rate due to the drugs),
the proliferation function p and the drug sensitivity functions µ1 have been chosen to be
simple decreasing affine functions of the resistance phenotype x: p(x) := a1+a2(1−x) and
µ1(x)= b1+b2(1−x) (µ2 being a sensitivity parameter to cytostatic infusion is taken constant,
not inducing resistance, contrary to the cytotoxic sensitivity µ1(x), whereby resistance occurs).
For each t, we also define ρ(t,r) =
∫ 1
0
n(t,r,x) dx (local density at radius r) and ρT(t) =∫ 1
0
ρ(t,r)r2 dr (global density).
The initial distribution of the cell population is illustrated on Figure 12. Its evolution under
constant doses of cytostatic or cytotoxic drugs is illustrated on Figure 13, and under combined
doses of bang-bang and constant controls on Figure 14.
The simulation illustrated by Figure 14 shows on an example (as a proof of concept) that
in periodic drug delivery strategies, one should never give cytotoxics on a constant scheme,
but that a bang-bang delivery of cytotoxics may be successful. This is in accordance with the
theoretical results of the previous Sections 4.1 and 4.2.
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Figure 12: Initial distribution of the cell population and its representation in the (r,x) plane (phenotype x arbitrarily
set to 0.5 to follow its trend under different conditions, see Figure 13).
Figure 13: Long-time evolution of phenotype x without drugs (a), under exposure to cytostatics (b) and to cytotoxics
(c) constant infusion (C-I). On the right panels, x is in ordinates and r, from 0 (centre of the spheroid) to 1 (outer
rim of the spheroid), in abscissae. One can see that without drugs, the phenotypes slowly reverts towards sensitivity,
that the cytostatic drug u2 has only small effects, whereas the cytotoxic drug u1 induces resistance [30].
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Figure 14: (a) Cytotoxic (constant infusion, C-I) with cytostatic (bang-bang infusion, BB-I) drug infusions. Plots of∫ 1
0 n(t,r,x)r
2dr in the (x,t) plane (left panel) and ρT(t) with time t (right panel). Bang-bang infusion of cytostatic
drugs together with constant infusion of cytotoxic drugs weakly affects the dynamics of cancer cells by comparison with
the case without therapies, apart from temporary reductions of the global population density. (b) Cytotoxic (BB-I)
with cytostatic (C-I) drug infusions. Plots of
∫ 1
0 n(t,r,x)r
2dr (left panel) and ρT(t) (right panel). Bang-bang infusion
of cytotoxic drugs together with constant delivery of cytostatic drugs can push the cancer cell population toward
extinction. The time unit is days. All values are normalised with respect to the initial global population density [30].
This example shows that in a periodic drug delivery framework, strategy (b) should clearly be better than strategy (a).
5 Conclusion: Why is evolution important in cancer? A list of chal-
lenging, though basic, questions on multicellularity and cancer
• (Admitted) cancer is a disease of multicellular organisms, that has been evidenced, in-
cluding in fossils, in the whole animal kingdom.
• (Admitted) cancer is the failure of maintenance of a coherent (=founded on stable cellular
differentiations) multicellularity, or else:
• (Admitted) cancer may be defined as a loss of cohesion of tissues and organs of a same
organism following failures in differentiation.
• Does there exist in the construction of multicellularity a qualitative succession (major
transitions) of emergences of families of genes responsible for 1. proliferation and apop-
tosis 2. differentiation (transcription factors?); 3. epigenetic control of differentiations?
In favour on this scenario, phylogenetic scenarios of evolution of mutations in acute
myeloid leukaemia (AML) go in the opposite direction with increasing malignancy [19].
• Some gene mutations predispose subjects to well-identified organ cancers: do these
genes play a role in the anatomic constitution of multicellularity?
• Evolution proceeds by tinkering [25], using every possible avaible material: what in such
a succession of tinkerings makes an organism viable but fragile?
• The genes that are altered in cancers are the same that serve multicellularity design [10,
12, 13, 52]: can we methodically collect these genes and their emergence, so as to better
understand the development of cancers?
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• What defines a same organism ? A ‘self’ that would be conserved during the sequences
of differentiations that in Man lead from the first embryonic cell to the ‘200 terminally
differentiated cell types’?
• What holds together, normally without conflict, the cell types (the interferon pathways??),
and what does the immune system recognise as non-self (foe rather than friend) in a can-
cer cell?
• Is there a relationship of such coherence with the major histocompatibility complex (MHC)?
What is its primary function, if not to ensure organism cohesion (of tissues), and how
does such coherence (of signals) operate?
• Can we parallel evolution of species and evolution of their immune system? Some en-
lightenment to collect genes active at multicellularity constitution?
• Admitting that loss of control of cell differentiations is the main cause of cancer, can we
speculate that all cancers have in their evolution an epigenetic origin or an epigenetic
mandatory step?
• Some is known of mutations in genes that control epigenetics (e.g., DNMT3A, TET2) in
early leukaemogenesis, and of genes of cell metabolism (IDH1, IDH2) in cancers (AML,
glioblastoma): can we propose and exemplify a standard scenario linking perturbations
of metabolism / perturbations of epigenetic control of differentiations / cancers?
• The energetic metabolism of the cell involves intercellular communications, that have
been reported to be disrupted in cancer: is the emergence of gap junctions essential in
the development of multicellularity and are perturbations of physiological gap junctions
a cause or a consequence of cancer in solid tumours? [45–47].
• Cancer cell populations seem to be able to switch between glycolytic and mitochondrial
respiratory phenotypes: do cancer cells shift easily from one to the other? In other words,
does a tumour practice a form of metabolic bet hedging?) [20].
• What are the advantages and drawbacks of these 2 phenotypes, glycolytic and respira-
tory? Efficiency of the tricarboxylic acid [TCA, aka Krebs] cycle vs. rapidity of anaerobic
glycolysis? When did the mitochondrial respiratory chain appear in evolution as a nec-
essary condition for the establishment of reliable intercellular communications?
• What is more relevant for stress response of a cell population (adaptable, as in the case of
a tumour): maintain a subpopulation of all-stress resistant cells, or maintain a subpopu-
lation of cells expressing ‘cold genes’ and able to launch different resistance mechanisms
in different cells? (... stochastically chosen?)
• Can bet hedging be seen as a ‘tumour strategy’ to diversify the responses of a plastic cell
population to deadly stress (as high doses of cytotoxic drugs) by launching different
stress response mechanisms in different cells? (ABC transporters, detoxication enzymes,
blocking influx, DNA repair, and others) [3].
• Does stress response induce derepression of cold genes? Presented in [50], this hypothesis
proposes that the existence of very ancient genes, constituted in a remote past of our
planet, makes plastic cell populations able to put at work different survival programs
in a state of emergency, with bet hedging, i.e., (stochastic or not) distribution of survival
strategies, in a cancer cell population.
• Does bet hedging shuffle phenotypes, setting favorable bases for the emergence of special-
isation [1, 32–35] and cooperativity in tumours [31, 36, 42], making them viable?
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